Dyadic Speeds Ebola Antigen Production in 15 Days, Validating C1 Platform for Outbreak Response — Dyadic International, Inc. (Dyadic Applied BioSolutions)

Event summary

Dyadic developed stable C1 cell lines and produced purified Bundibugyo Ebola antigens in ~15 days from plasmids.
Antigens delivered to Scripps Research for preclinical evaluation of a potential non-mRNA vaccine candidate.
$3.1M Gates Foundation grant fully received for respiratory syncytial virus and malaria monoclonal antibody programs.
C1 platform demonstrated antibody titers exceeding 12 g/L in seven days across multiple programs.

The big picture

Dyadic's rapid antigen production demonstrates the strategic value of its C1 platform for outbreak response, particularly where conventional mRNA vaccine development may be too slow. The global biologics sector's high-single-digit annual growth creates significant opportunity for platforms that can accelerate development and reduce costs. If validated across multiple programs, C1 could reshape biologics manufacturing by improving commercial viability and patient access in cost-sensitive markets.

What we're watching

Platform Adoption: Whether Dyadic's C1 platform can gain broader adoption in biologics manufacturing through licensing and partnerships.
Outbreak Response: The pace at which the C1 system can be deployed for other emerging infectious disease threats beyond Ebola.
Cost Efficiency: How potential elimination of viral-clearance steps in fungal production systems affects manufacturing costs and scalability.